CMS proposes risk adjustment payments for 2018

After halting, then restarting, payments for the healthcare insurance risk-adjustment program, CMS has proposed keeping the payments for the 2018 benefits rule. 

Previously, the agency restarted payments for the 2017 benefit year. The risk-adjustment payments program, designed as part of the Affordable Care Act, helps offset risk faced by insurers that accept higher-cost patients, by collecting payments from insurers with lower-risk patients and distributing funds to those who take higher-risk patients.

CMS halted payments and collections on July 7 due to a federal court decision that said the payment formula was based on flawed methodology. However, halting the payments posed a major threat to the stability of the healthcare insurance marketplace, and, after significant backlash from the industry, CMS reinstated the payments and published a final rule on July 30. The rule posted August 8 will ensure payments for the 2018 benefit year.

“Today’s proposed rule continues our effort to help stabilize the individual and small group markets,” CMS Administrator Seema Verma, MPH, said in a statement. “Our goal has been, and will continue to be, to stabilize the market and provide American consumers with more affordable health coverage options.” 

The 2018 proposed rule will be published on the Federal Register on Aug. 10, with a comment period that will run until Sept. 7.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.